REVENUE MEMORANDUM CIRCULAR NO. 119-2022 issued on August 8, 2022 publishes the July 20, 2022 letter from Food and Drug Administration (FDA) OIC-Director General Oscar G. Gutierrez, Jr. endorsing updates to the “List of VAT-Exempt Medicines” under Republic Act No. 11534 (CREATE Act), which now includes 150 mg + 100 mg Nirmatrelvir + Ritonavir film-coated tablet among the medicines prescribed for COVID-19 treatment.
         As clarified under Q&A No. 1 of Revenue Memorandum Circular No. 99-2021, the effectivity of the VAT exemption of the covered medicines and medical devices under the CREATE Act shall take effect on the date of publication by the FDA of the updates to the said list.